|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brent DelMonte, Vice President for Federal Government Relations |
Date | 04/20/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
TransPacific Partnership
Sanitary and Phytosanitary Issues
USDA/APHIS Agricultural Biotechnology Regulations
Efficient Science-Based Review of Biotech Products
National Environmental Policy Act Requirements
Coexistence of Production Systems
Biomass Crop Assistance Program (BCAP)
Farm Bill Reauthorization
EPA Regulations on Agricultural Biotechnology
EPA Notice on PIP Data Requirements
Reauthorization and Implementation of Pesticide Registration Improvement Act
Departments of the Interior, Environment, and Related Agencies Appropriations Act for FY 2013
Biotechnology Stewardship
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
Labeling
FDA Approval
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
Amendment to Restrict FDA Approval of GE Salmon
Export Registrations for Products with Expired Patents
Labeling of Genetically Engineered Crops
U.S. Government Policy
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
U.S. Policy on International Science-Based Regulations
Adventitious Presence (Low Level Presence)
U.S. Low Level Presence Policy
Foreign Agricultural Biotechnology Laws and Regulations
Low-Level Presence Foreign Government Policies
Discussions with EU on Animal Cloning
EU Biotechnology Bilateral Discussions
China Biotechnology Regulations
European Union Low Level Presence Policy
International Biotechnology Agreement
Regulatory Actions on Biological Pesticides
Agricultural Biotechnology Regulatory Reform and Modernization
Benefits of Ag-Biotech Research and Innovation
Funding for the USDA (Office of General Counsel, Biotechnology Regulatory Services, Animal Care & Veterinary Services (APHIS), Trade Activities (Office of the Secretary & Food Safety Inspection Service), Agriculture Research Service, Biofuels, Foreign Agriculture Service)
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
David |
Edwards |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
O'Mara |
|
|
|
Brent |
Del Monte |
|
|
|
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
Labeling
FDA Approval
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
Amendment to Restrict FDA Approval of GE Salmon
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2013
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for Veterinary Medicine, Scientific Infrastructure)
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
Funding for the USDA (Office of General Counsel, Biotechnology Regulatory Services, Animal Care & Veterinary Services (APHIS), Trade Activities (Office of the Secretary & Food Safety Inspection Service), Agriculture Research Service, Biofuels, Foreign Agriculture Service)
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
Funding for Bio-based Products
Energy and Water Development Appropriations Act for FY 2013
Funding for Biofuels
Energy and Water Development Appropriations Act for FY 2013
Funding for Biorefineries
Energy and Water Development Appropriations Act for FY 2013
Funding for Centers for Disease Control and Prevention Vaccine Programs
Departments of Labor, Education, and Related Agencies Appropriations Act for FY 2013
Funding for National Institutes of Health
Cures Acceleration Network
National Center of Advancing Translational Science (NCATS)
Departments of Labor, HHS, and Education, and Related Agencies Appropriations Act for FY 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Energy - Dept of, Natl Institutes of Health (NIH), Food & Drug Administration (FDA), White House Office, Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Schumaker |
|
|
|
Matt |
Carr |
|
|
|
Cathleen |
Enright |
|
|
|
Andrew |
Emmett |
|
|
|
Cartier |
Esham |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Sara |
Radcliffe |
|
|
|
Sarah |
Thornton Caswell |
|
|
|
Brent |
DelMonte |
|
|
|
Kelly |
Cappio |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CAW
16. Specific lobbying issues
Regulatory Actions on Biological Pesticides
Climate Change Benefits of Biofuels
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Energy - Dept of, Navy - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
O'Brien |
|
|
|
Matt |
Carr |
|
|
|
Sarah |
Thornton Caswell |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform
Implementation of H.R. 1249: The America Invents Act of 2011
World Trade Organization Special 301 Submissions
Genetic Resource Patent Disclosure Requirement
World Intellectual Property Organization
Intellectual Property International Enforcement
Compulsory Licensing
International IP Patent Law Harmonization
TransPacific Partnership
Data and Intellectual Property Protections for Pharmaceuticals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO), State - Dept of (DOS), U.S. Trade Representative (USTR), Justice - Dept of (DOJ), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lila |
Feisee |
|
|
|
Hans |
Sauer |
|
|
|
Charles |
Fritts |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Joseph |
Damond |
|
|
|
Roy |
Zwahlen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
USDA/APHIS Agricultural Biotechnology Regulations
Efficient Science-Based Review of Biotech Products
National Environmental Policy Act Requirements
Coexistence of Production Systems
Genetically Engineered (GE) Animals
Labeling
FDA Approval
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
Amendment to Restrict FDA Approval of GE Salmon
Labeling of Genetically Engineered Crops
U.S. Government Policy
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
Drug Safety and Review/Prescription Drug User Fee Act (PDUFA) Reauthorization
Critical Path Initiative
E-Pedigree and Anti-Counterfeiting
Regulatory Reforms for Innovative Products
Supply Chain Integrity
Conflicts of Interest
FDA Mission
Drug Shortages
Expedited Approval Pathways
Access to External Experts
Senate HELP Committee Discussion Draft
House Energy and Commerce Committee Discussion Draft
FDA Globalization Act (Discussion Draft)
H.R. 2245: Preserving Access to Life Saving Medicines Act of 2011
S. 296: Preserving Access to Life-Savings Medicines Act of 2011
S. 2113: Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act of 2011
H.R.3214: Food and Drug Administration Mission Reform Act of 2011
H.R.4132: Faster Access to Specialized Treatments (FAST) Act
H.R.3206: Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011
H.R.1483: Drug Safety Enhancement Act of 2011
H.R.2182: Generating Antibiotic Incentives Now Act of 2011
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for Veterinary Medicine, Scientific Infrastructure)
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP), Environmental Protection Agency (EPA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
David |
Edwards |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Sandra |
Dennis |
|
|
|
Melissa |
Bowie |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Matthew |
O'Mara |
|
|
|
Matthew |
Schumaker |
|
|
|
Brent |
Del Monte |
|
|
|
Cartier |
Esham |
|
|
|
Tom |
DiLenge |
|
|
|
Alyson |
Pusey |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biorefineries
Funding for Biorefineries
Energy and Water Development Appropriations Act for FY 2013
Biofuels
Economic Growth Impact/Potential of Advanced Biofuels
Biofuels Production Tax Credit Modification for Algae-based Biofuels
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Biofuels Production Tax Credit Extension
Next Generation Incentives: Farm Bill Reauthorization
Funding for Biofuels
Energy and Water Development Appropriations Act for FY 2013
Renewable Fuels Standard
Implementation of Energy Independence and Security Act of 2007
Regulatory Oversight
EPA Rulemaking on Life-cycle Greenhouse Gas Emissions Requirements
Bio-based Products
USDA Bio-Preferred Program
Economic Growth Impact/Potential of Advanced Bio-based Products
Tax Credit
Next Generation Incentives: Farm Bill Reauthorization
Expansion of DOE and USDA Loan Guarantee Programs
Funding for Bio-based Products
Energy and Water Development Appropriations Act for FY 2013
Renewable Chemicals
New Production Tax Credit/Revisions to Existing Tax Credits
S.2155: Farm Security and Rural Investment Act of 2002
S.847: The Safe Chemicals Act of 2011 (TSCA Reform Proposals)
Farm Bill Reauthorization: DOE Loan Guarantees
S.1764: Make It in America Tax Credit Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, Energy - Dept of, Agriculture - Dept of (USDA), Defense - Dept of (DOD), Navy - Dept of, U.S. SENATE, Environmental Protection Agency (EPA), White House Office, Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Thornton Caswell |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
Labeling
FDA Approval
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
Amendment to Restrict FDA Approval of GE Salmon
Labeling of Genetically Engineered Crops
U.S. Government Policy
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biorefineries
Funding for Biorefineries
Energy and Water Development Appropriations Act for FY 2013
Biofuels
Economic Growth Impact/Potential of Advanced Biofuels
Biofuels Production Tax Credit Modification for Algae-based Biofuels
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Biofuels Production Tax Credit Extension
Next Generation Incentives: Farm Bill Reauthorization
Funding for Biofuels
Energy and Water Development Appropriations Act for FY 2013
Renewable Fuels Standard
Implementation of Energy Independence and Security Act of 2007
Regulatory Oversight
EPA Rulemaking on Life-cycle Greenhouse Gas Emissions Requirements
Bio-based Products
USDA Bio-Preferred Program
Economic Growth Impact/Potential of Advanced Bio-based Products
Tax Credit
Next Generation Incentives: Farm Bill Reauthorization
Expansion of DOE and USDA Loan Guarantee Programs
Funding for Bio-based Products
Energy and Water Development Appropriations Act for FY 2013
Renewable Chemicals
New Production Tax Credit/Revisions to Existing Tax Credits
S.2155: Farm Security and Rural Investment Act of 2002
S.847: The Safe Chemicals Act of 2011 (TSCA Reform Proposals)
Farm Bill Reauthorization: DOE Loan Guarantees
S.1764: Make It in America Tax Credit Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Energy - Dept of, Agriculture - Dept of (USDA), Defense - Dept of (DOD), Navy - Dept of, Environmental Protection Agency (EPA), White House Office, Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Thornton Caswell |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Biosimilars
Biosimilars User Fee Act of 2012 (Discussion Draft)
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Funding for National Institutes of Health
Cures Acceleration Network
National Center of Advancing Translational Science (NCATS)
Departments of Labor, HHS, and Education, and Related Agencies Appropriations Act for FY 2013
Funding for Centers for Disease Control and Prevention Vaccine Programs
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2013
Vaccine Access/Financing
Adult Immunization Policies
Tax for Seasonal Influenza Funding
340B Drug Pricing Program
HRSA Implementation of Program Changes
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Therapeutic Discovery Project Tax Credit
Extension
Rare Pediatric & Tropical Disease Drug Development
Drug Safety and Review/Prescription Drug User Fee Act (PDUFA) Reauthorization
Critical Path Initiative
E-Pedigree and Anti-Counterfeiting
Regulatory Reforms for Innovative Products
Supply Chain Integrity
Conflicts of Interest
FDA Mission
Drug Shortages
Expedited Approval Pathways
Access to External Experts
Senate HELP Committee Discussion Draft
House Energy and Commerce Committee Discussion Draft
FDA Globalization Act (Discussion Draft)
H.R. 2245: Preserving Access to Life Saving Medicines Act of 2011
S. 296: Preserving Access to Life-Savings Medicines Act of 2011
S. 2113: Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act of 2011
H.R.3214: Food and Drug Administration Mission Reform Act of 2011
H.R.4132: Faster Access to Specialized Treatments (FAST) Act
H.R.3206: Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011
H.R.1483: Drug Safety Enhancement Act of 2011
H.R.2182: Generating Antibiotic Incentives Now Act of 2011
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for Veterinary Medicine, Scientific Infrastructure)
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013
Independent Payment Advisory Board
H.R. 5: Protecting Access to Healthcare Act of 2011
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2013
Biodefense Research, Development and Procurement
S 1855: Pandemic and All Hazards Preparedness Act (PAHPA) Reauthorization of 2011
TransPacific Partnership
Data and Intellectual Property Protection for Pharmaceuticals
Reimbursement for Innovative Products
Medicare Part B Physician-Administered Products
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), U.S. Trade Representative (USTR), Natl Institutes of Health (NIH), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shelly |
Mui-Lipnik |
|
|
|
Roy |
Zwahlen |
|
|
|
Sandra |
Dennis |
|
|
|
Andrew |
Emmett |
|
|
|
Matthew |
Schumaker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sara |
Radcliffe |
|
|
|
Phyllis |
Arthur |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Cartier |
Esham |
|
|
|
Lila |
Feisee |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Laurel |
Todd |
|
|
|
Brent |
Del Monte |
|
|
|
Alan |
Eisenberg |
|
|
|
Charles |
Fritts |
|
|
|
Alyson |
Pusey |
|
|
|
Kelly |
Cappio |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2013
Biodefense Research, Development and Procurement
S 1855: Pandemic and All Hazards Preparedness Act Reauthorization of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melissa |
Bowie |
|
|
|
Anna |
Weinstein |
|
|
|
Phyllis |
Arthur |
|
|
|
Matthew |
Schumaker |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
|
Sara |
Radcliffe |
|
|
|
Kelly |
Cappio |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Biodefense Research, Development and Procurement
S 1855: Pandemic and All Hazards Preparedness Act Reauthorization of 2011
Funding for National Institutes of Health
Cures Acceleration Network
National Center of Advancing Translational Science (NCATS)
Departments of Labor, HHS, and Education, and Related Agencies Appropriations Act for FY 2013
Rare Pediatric & Tropical Disease Drug Development
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Schumaker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tracey |
LaTurner |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Phyllis |
Arthur |
|
|
|
Cartier |
Esham |
|
|
|
Kelly |
Cappio |
|
|
|
Brent |
Del Monte |
|
|
|
Sara |
Radcliffe |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Reimbursement for Innovative Products
Medicare Part B Physician-Administered Products
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Schumaker |
|
|
|
Melissa |
Bowie |
|
|
|
Jeanne |
Haggerty |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Laurel |
Todd |
|
|
|
Alyson |
Pusey |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Research & Development Tax Credit Extension
H.R. 3606: Jumpstart Our Business Start-ups (JOBS) Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shelly |
Mui-Lipnik |
|
|
|
Charles |
Fritts |
|
|
|
Alan |
Eisenberg |
|
|
|
Brent |
Del Monte |
|
|
|
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Expansion of Exemption under SEC Regulation A
H.R. 3606: Jumpstart Our Business Start-ups (JOBS) Act
Sarbanes Oxley Section 404 (b)
H.R. 3606: Jumpstart Our Business Start-ups (JOBS) Act
S.1933: Reopening American Capital Markets to Emerging Growth Companies Act of 2011
H.R. 3213: Small Company Job Growth and Regulatory Relief Act of 2011
Small Business Early-Stage Investment
H.R. 3606: Jumpstart Our Business Start-ups (JOBS) Act
Therapeutic Discovery Project Tax Credit
Extension
Capital Formation Investment Incentives
Reform of SEC Regulation D
H.R. 3606: Jumpstart Our Business Start-ups (JOBS) Act
S. 1831/H.R. 2940: Access to Capital for Job Creators Act of 2011
Shareholder Reporting Threshold
S. 1824/H.R. 2167: Private Company Flexibility and Growth Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
Alan |
Eisenberg |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tooshar |
Swain |
|
|
|
Matthew |
Schumaker |
|
|
|
Brent |
Del Monte |
|
|
|
Charles |
Crain |
|
|
|
.Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Vaccine Access/Financing
Tax for Seasonal Influenza Funding
Bio-based Products
Tax Credit
Therapeutic Discovery Project Tax Credit
Extension
Biofuels
Biofuels Production Tax Credit Modification for Algae-based Biofuels
Biofuels Production Tax Credit Extension
Research & Development Tax Credit Extension
H.R. 3606: Jumpstart Our Business Start-ups (JOBS) Act
Capital Formation Investment Incentives
Renewable Chemicals
New Production Tax Credit/Revisions to Existing Tax Credits
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Dana |
O'Brien |
|
|
|
Charles |
Crain |
|
|
|
Rina |
Singh |
|
|
|
Charles |
Fritts |
|
|
|
Sarah |
Thornton Caswell |
|
|
|
Kelly |
Cappio |
|
|
|
Phyllis |
Arthur |
|
|
|
Tooshar |
Swain |
|
|
|
Alan |
Eisenberg |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
World Trade Organization Special 301 Submissions
Export Registrations for Products with Expired Patents
U.S. Policy on International Science-Based Regulations
Intellectual Property International Enforcement
Compulsory Licensing
Foreign Agricultural Biotechnology Laws and Regulations
Low-Level Presence Foreign Government Policies,
China Biotechnology Regulations
Discussions with EU on Animal Cloning
EU Biotechnology Bilateral Discussions
European Union Low Level Presence Policy
International Biotechnology Agreement
Genetic Resource Patent Disclosure Requirement
World Intellectual Property Organization
TransPacific Partnership
Data and Intellectual Property Protection for Pharmaceuticals
Sanitary and Phytosanitary Issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), State - Dept of (DOS), Patent & Trademark Office (PTO), Commerce - Dept of (DOC), Food & Drug Administration (FDA), Justice - Dept of (DOJ), Office of Science & Technology Policy (OSTP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melissa |
Bowie |
|
|
|
David |
Edwards |
|
|
|
Matthew |
Schumaker |
|
|
|
Lila |
Feisee |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
|
Roy |
Zwahlen |
|
|
|
Matthew |
O'Mara |
|
|
|
Cathleen |
Enright |
|
|
|
Brent |
Del Monte |
|
|
|
Joseph |
Damond |
|
|
|
Anna |
Weinstein |
|
|
|
Charles |
Fritts |
|
|
|
Dana |
O'Brien |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
PHA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: BIO maintains a list of all of its members on its website at http://bio.org/membership/index.asp
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |